|Vector Type||Mammalian Expression Vector|
|Expression Method||Constiutive, Stable / Transient|
|Selection In Mammalian Cells||Hygromycin|
FLAG-tag, or FLAG octapeptide, is a polypeptide protein tag that can be added to a protein using recombinant DNA technology. It can be used for affinity chromatography, then used to separate recombinant, overexpressed protein from wild-type protein expressed by the host organism. It can also be used in the isolation of protein complexes with multiple subunits.
A FLAG-tag can be used in many different assays that require recognition by an antibody. If there is no antibody against the studied protein, adding a FLAG-tag to this protein allows one to follow the protein with an antibody against the FLAG sequence. Examples are cellular localization studies by immunofluorescence or detection by SDS PAGE protein electrophoresis.
The peptide sequence of the FLAG-tag from the N-terminus to the C-terminus is: DYKDDDDK (1012 Da). It can be used in conjunction with other affinity tags, for example a polyhistidine tag (His-tag), HA-tag or Myc-tag. It can be fused to the C-terminus or the N-terminus of a protein. Some commercially available antibodies (e.g., M1/4E11) recognize the epitope only when it is present at the N-terminus. However, other available antibodies (e.g., M2) are position-insensitive.
|人 HRAS 基因全長cDNA ORF克隆 (表達載體), C-GFPSpark 標籤||HG12059-ACG|
|人 HRAS 基因全長cDNA ORF克隆 (表達載體), C-OFPSpark 標籤||HG12059-ACR|
|人 HRAS 基因全長cDNA ORF克隆 (表達載體), C-Flag 標籤||HG12059-CF|
|人 HRAS 基因全長cDNA ORF克隆 (表達載體), C-His 標籤||HG12059-CH|
|人 HRAS 基因全長cDNA ORF克隆 (表達載體), C-Myc 標籤||HG12059-CM|
|人 HRAS 基因全長cDNA ORF克隆 (表達載體), C-HA 標籤||HG12059-CY|
|人 HRAS 基因全長cDNA ORF(克隆載體)||HG12059-G|
|人 HRAS 基因全長cDNA ORF克隆 (表達載體), N-Flag 標籤||HG12059-NF|
|人 HRAS 基因全長cDNA ORF克隆 (表達載體), N-His 標籤||HG12059-NH|
|人 HRAS 基因全長cDNA ORF克隆 (表達載體), N-Myc 標籤||HG12059-NM|
|人 HRAS 基因全長cDNA ORF克隆 (表達載體), N-HA 標籤||HG12059-NY|
|人 HRAS 基因全長cDNA ORF克隆 (表達載體)||HG12059-UT|
HRas, also known as HRAS, belongs to the small GTPase superfamily, Ras family and is widely expressed. It functions in signal transduction pathways. HRas can bind GTP and GDP, and they have intrinsic GTPase activity. It undergoes a continuous cycle of de- and re-palmitoylation, which regulates its rapid exchange between the plasma membrane and the Golgi apparatus. Defects in HRAS are the cause of faciocutaneoskeletal syndrome (FCSS). FCSS is arare condition characterized by prenatally increased growth, postnatal growth deficiency, mental retardation, distinctive facial appearance, cardiovascular abnormalities, tumor predisposition, skin and musculoskeletal abnormalities. Defects in HRAS also can cause congenital myopathy with excess of muscle spindles. HRAS deficiency may be a cause of susceptibility to Hurthle cell thyroid carcinoma. It has been shown that defects in HRAS can cause susceptibility to bladder cancer which is a malignancy originating in tissues of the urinary bladder. It often presents with multiple tumors appearing at different times and at different sites in the bladder. Most bladder cancers are transitional cell carcinomas. They begin in cells that normally make up the inner lining of the bladder. Other types of bladder cancer include squamous cell carcinoma (cancer that begins in thin, flat cells) and adenocarcinoma (cancer that begins in cells that make and release mucus and other fluids). Bladder cancer is a complex disorder with both genetic and environmental influences. Defects in HRAS are the cause of oral squamous cell carcinoma.